France
- Latest Posts
News and Trends 11 Apr 2023
Calida Therapeutics launches to tackle thrombo-inflammatory disorders
Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding from venture capital company AdBio partners. The funds will be used to conduct additional in vivo proofs of concept and select a lead candidate. Calida […]
News and Trends 9 Mar 2023
Iktos raises €15.5M to expand AI drug discovery technologies
Iktos, a company specializing in artificial intelligence (AI) for new drug discovery, has closed a €15.5 million ($16.4 million) Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. This financing will enable Iktos to further develop its AI and drug discovery capabilities and expand its existing SaaS software […]
News and Trends 14 Feb 2023
BiPER Therapeutics raises €1.25M to develop small molecules to treat gastrointestinal cancers
BiPER Therapeutics, a French preclinical biotechnology company developing first-in-class drug candidates targeting BiP protein to treat gastrointestinal cancers, has raised €1.25 million ($1.35 million) in seed funding. BiPER Therapeutics received €300,000 in dilutive funds from WiSeed via WiClub Santé 2, €500,000 in convertible bonds from Bpifrance, and €450,000 in grants as part of the i-Lab […]
News and Trends 7 Feb 2023
Mnemo Therapeutics and Institut Curie studies lead to cancer-specific targets
Mnemo Therapeutics, a French biotechnology company developing immunotherapies, has announced publication of two scientific studies developed at Institut Curie, its closest academic collaborator, in the journal Science Immunology. The publications reveal TE-exon splicing junctions act as a source of novel recurrent, cancer-specific targets and have potential implications for developing more effective and less toxic immunotherapies. […]
News and Trends 27 Jan 2023
Onxeo to study prostate cancer drug
French biotech company Onxeo S.A. has given an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first U.S. clinical study site, Next Oncology San Antonio. This phase 1b/2 multicenter, basket trial intends to assess the safety and preliminary activity of AsiDNA in combination with olaparib in patients […]
News and Trends 24 Jan 2023
First leukemia patient dosed with SMART101
Smart Immune has announced that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial SloanKettering Cancer Center (MSK). The phaseI/II trial is a multicenter, open-label, first-in-human study expected to enroll up to 36 adult and pediatric patients with hematological malignancies, […]
News and Trends 9 Jan 2023
ErVaccine raises €4.5M to start therapeutic cancer vaccine trial
ErVaccine Technologies, announces the closing of a €4.5 million ($4.8 million) seed round, including dilutive and non-dilutive funds, with Seventure and Bpifrance as part of the Aide au Développement de l’Innovation (ADI) program. ErVaccine is a biotech company and spin-off from the Centre Léon Bérard-Centre de Recherche en Cancérologie de Lyon, France, which develops next-generation […]
News and Trends 6 Jan 2023
Transgene approved for IV oncolytic virus trial
Transgene has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I clinical trial of TG6050. TG6050 is a novel oncolytic virus (OV) that will be administered intravenously in patients with advanced non-small cell lung cancer (NSCLC). Transgene is […]
News and Trends 3 Jan 2023
Sensorion announces first patient enrolled in cisplatin-induced ototoxicity trial
Sensorion has announced that the first patient has been enrolled in its phase 2a proof of concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, […]
News and Trends 1 Jan 2023
Watch: Addressing IP with Starting Bloch
Starting Bloch is a French-headquartered company helping companies navigate the world of IP and patents. The company’s Patman platform was developed to assist companies with patents, licenses and trademarks. The company also assists companies addressing fundraising, as well as helping with management and tech transfer. Patman gives companies a calendar of events to address issues […]
Startup Scout 13 Dec 2022
Biomemory is making DNA hard drives cheap and sustainable
The world is running out of ways to store the mountains of data we produce. Biomemory is creating DNA-based hard drives that could store this information cheaply, sustainably and for centuries. Society has advanced very far in technologies to store critical data, moving from punched cards and floppy disks in the 20th century to hard […]
ADVERTISEMENT